Showing 4021-4030 of 5300 results for "".
- Topical NAC Plus Doxycycline Shows Benefit in Moderate Acnehttps://practicaldermatology.com/news/topical-nac-plus-doxycycline-shows-benefit-in-moderate-acne/2486948/Topical N-acetylcysteine (NAC) plus doxycycline was associated with greater improvement than benzoyl peroxide (BPO) plus doxycycline in patients
- Rapid Weight Loss Brings Expanding Soft Tissue Concerns to Dermatologyhttps://practicaldermatology.com/news/rapid-weight-loss-brings-expanding-soft-tissue-concerns-to-dermatology/2486936/A new analysis suggests rapid weight loss from GLP-1 agents, bariatric surgery, or lifestyle change is associated with measurable declines in skin elasticity and soft tissue volume.Rapid and intentional weight loss (driven by bariatric surgery, glucagon-l
- Analysis: PRS Improves Melanoma Risk Predictionhttps://practicaldermatology.com/news/tildrakizumab-matches-risankizumab-guselkumab-in-mid-term-psoriasis-outcomes/2486903/A polygenic risk score (PRS) improved prediction of invasive cutaneous melanoma when added to an established clinical risk model, according to findings from a recent genome-wide association analysis. The PRS was derived from a
- Dr. Miriam Bettencourt Speaks on Measles Resurgence and the Dermatologist’s Rolehttps://practicaldermatology.com/news/dr-miriam-bettencourt-speaks-on-measles-resurgence-and-the-dermatologists-role/2486877/As the ominous music from the “Mission Impossible” movies played over the speakers, a dramatic voice spoke: “Good morning, doctors. Sixty years of safe and effective vaccine has resulted in the eradication of measles. Recently, however, a distrust of science has pr
- AQUA Announces Partnership with Steele Dermatologyhttps://practicaldermatology.com/news/aqua-announces-partnership-with-steele-dermatology/2486768/AQUA Dermatology has announced a new partnership with Steele Dermatology, expanding its presence in the Atlanta metropolitan area, according to a press release.AQUA, backed by private equity firms Gryphon Investors and GTCR, continues to scale its network
- SEEN Launches Dermatologist-Designed Clarifying Shampoo as Scalp Care Trend Surgeshttps://practicaldermatology.com/news/seen-launches-dermatologist-designed-clarifying-shampoo-as-scalp-care-trend-surges/2486594/As scalp care continues to gain momentum within the broader beauty and wellness industry, dermatologist-founded brand SEEN is expanding its portfolio with the launch of its new Scalp Clarifying Shampoo, a product designed to bridge the gap between hair care and skin
- Rademikibart Shows High Long-Term Efficacy in Atopic Dermatitishttps://practicaldermatology.com/news/rademikibart-shows-high-long-term-efficacy-in-atopic-dermatitis/2486495/Rademikibart, a next-generation anti–IL-4 receptor alpha monoclonal antibody, demonstrated robust and sustained efficacy in moderate-to-severe atopic dermatitis (AD) through 52 weeks, according to Phase 3 RADIANT-AD data presented by Cheng Zhou, MD, at the American Academy of Dermatology (AAD) 20
- Nemolizumab Shows Efficacy in Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/nemolizumab-shows-efficacy-in-pediatric-atopic-dermatitis/2486457/Nemolizumab, an IL-31 receptor alpha (IL-31Rα) antagonist, demonstrated favorable pharmacokinetics, sustained efficacy, and a consistent safety profile in children aged 2 to 11 years with moderate-to-severe atopic dermatitis (AD), according to Phase 2 data presented by Linda Stein Gold, MD, at th
- Upadacitinib Shows Strong Hair Regrowth in Alopecia Areatahttps://practicaldermatology.com/news/upadacitinib-shows-strong-hair-regrowth-in-alopecia-areata/2486456/Upadacitinib demonstrated robust efficacy in both adolescents and adults with severe alopecia areata (AA), with particularly strong responses observed in younger patients, according to a subgroup analysis of two Phase 3 trials presented by Melinda Gooderham, MD, MSc, at the American Academy of De
- IL-15 Blockade Plus Phototherapy Shows Promise in Vitiligohttps://practicaldermatology.com/news/il-15-blockade-plus-phototherapy-shows-promise-in-vitiligo/2486454/Targeting IL-15 with ordesekimab in combination with narrowband ultraviolet B (nbUVB) phototherapy led to greater repigmentation in patients with non-segmental vitiligo, according to results from a randomized, placebo-controlled trial presented by Brett King, MD, PhD, at the American Academy of D